This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. One aspect that is extremely promising about radiopharmaceutical therapeutics is that they do not give a patient the sideeffects that are commonly experienced with chemotherapy.
As we enter into the age of precision medicine, AI will be a critical tool to determine, with the help of disease knowledge graphs, which indications, associations, contraindications, sideeffects, genetic markers, drug targets, drug carriers, and interactions to take into account on a case-by-case basis. AI isn’t coming for your job.
Regardless of the tactics and strategies employed, I would encourage more biopharma professionals to get personally involved in patient engagement programs. Typically, we think of patient partnerships in terms of their external impact—for example, to help educate doctors and payers. Different patients have unique needs. Anthony Yanni.
I worked as a hospital doctor for several years and then as a GP for several years, and it became very apparent that there was not enough information for patients to help them to better understand their illnesses, better understand their treatment [and] what to do with their medications. Dr. Grace Lomax : Yes, happily.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content